Inspiratory Muscle Training in Nemaline Myopathy (NEMTRAIN)

Title: 
Inspiratory Muscle Training in Nemaline Myopathy (NEMTRAIN)
Recruitment Status: 
Status Last Updated: 
October 25, 2019
Clinical Phenotype(s): 
Study Purpose: 

Nemaline myopathy is a rare congenital myopathy. Respiratory failure is the main cause of death in these patients. The primary objective of this study is to determine the effect of a 8-week inspiratory muscle training program on respiratory muscle function in nemaline myopathy patients. The secondary objective is to determine respiratory muscle function in nemaline myopathy patients and its correlation with clinical severity and general neuromuscular function. The nemaline myopathy patients will be included in the first phase for a clinical characterization. From this phase patients will be selected for the second phase, which is a controlled before-after trial of inspiratory muscle training. The primary outcome is the change in maximal inspiratory pressure (MIP) after active inspiratory muscle training

Intervention/Treatment: 
Device: Threshold IMT, Philips Respironics, Murrysville, PA, USA
Study Description: 

Rationale: Nemaline myopathy is a group of congenital, hereditary neuromuscular disorders with variable symptoms such as muscle weakness, swallowing dysfunction, and dysarthria. Respiratory failure is the main cause of death in nemaline myopathy and occurs even in ambulant patients who otherwise appear to be only mildly affected; respiratory muscle weakness may even be the presenting feature. Inspiratory muscle training has shown to increase inspiratory muscle strength in patients with other neuromuscular disorders. It is hypothesized that inspiratory muscle training improves respiratory muscle function in nemaline myopathy patients with respiratory muscle weakness.

Objective: The primary objective is to determine the effect of a 8-week inspiratory muscle training program on respiratory muscle function in nemaline myopathy patients. The secondary objective is to determine respiratory muscle function in nemaline myopathy patients and its correlation with clinical severity and general neuromuscular function.

Study design: The study consist of two phases. Phase 1: A screening phase with an open design from which patients will be selected for the second phase. Phase 2: A controlled before-after trial of inspiratory muscle training. The 2 conditions tested are sham IMT and active IMT.

Study population: Nemaline myopathy patients from the local neuromuscular database will be recruited. Furthermore, other centres in the Netherlands will be contacted to expand the database of nemaline myopathy patients. Phase 2 requires 23 patients.

Intervention: Active IMT consists of 15 minutes of IMT, twice a day, 5 days per week for 8 weeks, at a training workload of 30% of MIP using a resistive inspiratory muscle training device. Sham IMT consists of similar training regime using a resistive inspiratory muscle training device where the resistance has been removed.

Main study parameters/endpoints: The primary outcome parameter is the change in maximal inspiratory pressure (MIP) after active inspiratory muscle training.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The intervention of inspiratory muscle training is not associated with any risks, but can be challenging in patients with respiratory muscle weakness to perform. There will be three visits to the hospital in 16 weeks. The first visit has a maximal duration of 6 hours (including breaks) and the other two visits 1.5 hour. During these visits several tests and physical examinations will be performed. Some of the tests may cause some physical discomfort, but none of them carry any risk. Patients may benefit from participating in this study by developing improved respiratory muscle function as a result of the inspiratory muscle training.

Study Type: 
Official Title: 
Inspiratory Muscle Training in Patients With Nemaline Myopathy
Study Start Date: 
October 10, 2018
Study Completion Date: 
December 2020
Primary Objective(s): 
  1. Change of maximal inspiratory pressure (cmH2O) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ]
  • Obtained with handheld device
Secondary Objective(s): 
  1. Change of diaphragm thickness (mm) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with ultrasound
  2. Change of diaphragm thickening (ratio) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with ultrasound
  3. Change of diaphragm excursion (cm) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with ultrasound
  4. Change of peak cough flow (L/s) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld spirometry
  5. Change of forced vital capacity (% predicted) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld spirometry
  6. Change of forced expiratory volume in the first second (% predicted) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld spirometry
  7. Change of peak expiratory flow (L/s) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld spirometry
  8. Change of (Slow) vital capacity (% predicted) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld spirometry in sit and supine
  9. Change of sniff nasal inspiratory pressure (cmH2O) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld device
  10. Change of maximal expiratory pressure (cmH2O) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Obtained with handheld device
  11. Change of twitch mouth pressure (cmH2O) [ Time Frame: Baseline, after 8 weeks sham IMT, after 8 weeks active IMT ] Measured after bilateral phrenic nerve stimulation
  12. Maximal voluntary contraction (N) [ Time Frame: Baseline ] Handgrip ergonometer
  13. Rate of muscle relaxation (N/s) [ Time Frame: Baseline ] Measured by transcranial magnetic stimulation
  14. Motor Function Measure test [ Time Frame: Baseline ] The items of the MFM are classified in 3 domains: D1: Standing and transfers (13 items, sub score range 0-39) D2: Axial and proximal motor function (12 items, sub score range 0-36) D3: Distal motor function (7 items, sub score range 0-21) Each item is scored on a 0-3 scale. Each sub score will be calculated as the percentage of total possible score achieved. Higher scores indicate a better outcome. The range of the total score is 0-96, again recalculated as the percentage of total possible score achieved.
  15. 6-minute walk test [ Time Frame: Baseline ] This test assesses distance walked over 6 minutes as a submaximal test of aerobic capacity/endurance. The outcome is compared to the reference values.
  16. Falls [ Time Frame: 100-day period from baseline on ] The occurence of falls will be investigated retrospectively and prospectively during a 100-day period by questions composed by the investigators.
  17. Mini-BESTest: Balance Evaluation Systems Test (Balance test for adults) [ Time Frame: Baseline ] This test consists of several domains of balance and consequently of several sub scores: Anticipatory sub score 0-6 Reactive postural control 0-6 Sensory orientation sub score 0-6 Dynamic gait sub score 0-10 The sub scores are added up to a total score with a range of 0-28. Higher values represent a better outcome.
  18. Pediatric Balance Scale (Balance test for children) [ Time Frame: Baseline ] This test consists of 14 item. The participant can score 0-4 on each item, with a maximum score of 56. Higher values represent a better outcome.
  19. The RAND 36-Item Health Survey [ Time Frame: Baseline ] This questionnaire addresses eight concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. Scoring the RAND 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key. All items are scored so that a high score defines a more favourable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.
  20. Measurement model for the pediatric quality of life inventory: PedsQL [ Time Frame: Baseline ] This questionnaire consists of 8 items on physical functioning, 5 items on emotional functioning, 5 items on social functioning, and 5 items on school functioning. Each item is scored on a 0-4 scale. The items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate a better outcome. To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. The Physical Health Summary Score is the same as the Physical Functioning Scale Score. To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales.
Eligibility: 

Ages Eligible for Study: 6 Years to 80 Years (Child, Adult, Older Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria: 
  • Genetically-confirmed nemaline myopathy (mutations in one of the genes causing nemaline myopathy: TPM3, NEB, ACTA1, TPM2, TNNT1, KBTBD13, CFL2, KLHL40, KHLH41, LMOD3, MYPN, RYR1)
  • Informed consent from participant or legal representative
  • Age-range: between the age of 6-80 years
Exclusion Criteria: 
  • History of another condition that affects respiratory muscle strength or function (e.g. COPD)
Study Site(s)/Location(s): 

Netherlands

Radboud University Medical Center

Nijmegen, Netherlands

Sponsors & Collaborators: 

Radboud University

Principal Investigator(s): 

Baziel van Engelen, Prof. PhD - Promotor

For more information, please contact the Study Coordinator: 

Contact:  Jonne Doorduin, PjD

Email: jonne.doorduin@radboudumc.nl

Phone: 0243615099

ClinicalTrials.gov ID: 
NCT03728803